Regulated production of proteins from muscle using gene transfer: potential therapeutic applications

Bibliography

• HERZOG RW, YANG EY, COUTO LB et al.: Long-term correction of canine hemophilia B by gene transfer of blood coagulation Factor IX mediated by adeno-associated viral vector. Nat. Med. (1999) 5:56–63.
   PubMed Web of Science ®Google Scholar
• •Use of an AAV gene therapy approach for long-term correction of a genetic defect in a large animal model.
   Google Scholar
• FRIED MW: Side effects of therapy of hepatitis C and their management. Hepatology (2002) 5\(Suppl. 1):5237–5244.
   Google Scholar
• RYFFEL B: Safety of human recombinant proteins. Biomed. Environ. Sci. (1997) 1:65–72.
   Google Scholar
• HERZOG RW, HAGSTROM JN, KUNG S et al.: Stable gene transfer andexpression of human blood coagulation Factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Nati Acad. Sci. USA (1997) 94:5804–5809.
   PubMed Web of Science ®Google Scholar
• FE WELL JG, MACLAUGHLIN F, MEHTA V et al.: Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol. Ther (2001) 3:574–583.
   PubMed Web of Science ®Google Scholar
• RIZZUTO G, CAPPELLETTI M, MENNUNI C et al: Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure. Hum. Gene Ther. (2000) 11:1891–1900.
   PubMed Web of Science ®Google Scholar
• •Delivery of plasmids with electroporation to produce high level transgene expression and correction of anaemia.
   Google Scholar
• PAYEN E, BETTAN M, ROUYER- FESSARD P, BEUZARD Y, SCHERIVIAN D: Improvement of mouse beta-thalassemia by electrotransfer of erythropoietin cDNA. Exp. Hematol (2001) 3:295–300.
   Google Scholar
• SOMIARI S, GLASSPOOL-MALONE J, DRABICK JJ et al.: Theory and in vivo application of electroporative gene delivery. Ther. (2000) 2:178–187.
   Google Scholar
• MACCOLL GS, GOLDSPINK G, BOULOUX PM: Using skeletal muscle as an artificial endocrine tissue. J. Endocrinol (1999) 162:1–9.
   PubMed Web of Science ®Google Scholar
• CHAO H, LIU Y, RABINOWITZ J et al.: Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Ma Ther. (2000) 2:619–623.
   PubMed Web of Science ®Google Scholar
• MIR LM, BUREAU ME RANGARA R et al.: Long-term high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. Grit. Rev Acad. Sci.111(1998) 321:893-899.
   Google Scholar
• POLLER WC, FECHNER H, NOUTSIAS M et al.: Highly variable expression of virus receptors in the human cardiovascular system Implications for cardiotropic viral infections and gene therapy. Z KardioL (2002) 91:978–991.
   PubMedGoogle Scholar
• MARSHALL DJ, LEIDEN JM: Recent advances in skeletal-muscle based gene therapy. Curr. Opin. Genet. Dev. (1998) 8:360–365.
   PubMed Web of Science ®Google Scholar
• SMITH LC, NORDSTROM JL: Advances in plasmid gene delivery and expression in skeletal muscle. Curt: Opin. Mol. Ther. (2000) 2:150–154.
   PubMed Web of Science ®Google Scholar
• LI S, HUANG L: Nonviral gene therapy: promises and challenges. Gene. Ther. (2000) 7:31–34.
   PubMed Web of Science ®Google Scholar
• HIGH K: Gene transfer as an approach to treating hemophilia. Circ. Res. (2001) 88:137–144.
   PubMed Web of Science ®Google Scholar
• AMALFITANO A, PARKS RJ: Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Cup: Gene Ther (2002) 2:111–133.
   PubMedGoogle Scholar
• LIU PQ, REBAR EJ, ZHANG L et al: Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J. Biol Chem. (2001) 276:11323–11334.
   Google Scholar
• GOSSEN M, BUJARD H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. NatL Acad. Sci. USA (1992) 89:5547–5551.
   PubMed Web of Science ®Google Scholar
• ••Description of the tetracycline-repressiblegene expression system.
   Google Scholar
• VAN SLOUN PP, LOHMAN PH, VRIELING H: The design of a new mutation model for active genes: expression of the Escherichia coil lac operon in mammalian cells. MutaL Res. (1997) 382:21–33.
   PubMed Web of Science ®Google Scholar
• FUSSENEGGER M, MORRIS RP, FUX C et al.: Streptogramin-based gene regulation systems for mammalian cells. Nat. Biotechnol (2000) 18:1203–1208.
   PubMed Web of Science ®Google Scholar
• WANG Y, O& MALLEY BW JR, TSAI SY, O'MALLEY BW: A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. USA (1994) 91:8180–8184.
   PubMed Web of Science ®Google Scholar
• ••Description of the antiprogestin-induciblegene regulation system.
   Google Scholar
• PUTZER BM, STIEWE T, CRESPO F, ESCHE H: Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy. Gene Ther. (2000) 7:1317–1325.
   PubMed Web of Science ®Google Scholar
• NO D, YAO TP, EVANS RM: Eedysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. USA 0996) 93:3346–3351.
   Google Scholar
• NARUMI K, KOLIMA A, CRYSTAL RG: Adenovirus vector-mediated perforin expression driven by a glucocorticoid-inducible promoter inhibits tumor growth in vivo. Am. I Respir. Cell MM. Biol. (1998) 19:936–941.
   PubMed Web of Science ®Google Scholar
• RIVERA VM, CLACKSON T,NATESAN S et al.: A humanized system for pharmacologic control of gene expression. Nat. Med. (1996) 2:1028–1032.
   Google Scholar
• ••Description of the raparnycin-induciblegene regulation system.
   Google Scholar
• AGHA-MOHAMMADI S, LOTZE MT: Regulatable systems: applications in gene therapy and replicating viruses. J.Invest. (2000) 105:1177–1183.
   Google Scholar
• •Review of the tetracyline, mifepristone, ecdysone and raparnycin regulatable systems.
   Google Scholar
• NORDSTROM JL: Expression systems: regulated gene expression. In: Pharmaceutical Gene Delivery Systems AP Rolland and SM Sullivan (Eds), Marcel Dekker, Inc., New York, (2003).
   Google Scholar
• GOSSEN M, FREUNDLIEB S, BENDER G, MULLER G, HILLEN W, BUJARD H: Transcriptional activation by tetracyclines in mammalian cells. Science (1995) 268:1766–1769.
   PubMed Web of Science ®Google Scholar
• ••Description of the tetracycline-induciblegene regulation system.
   Google Scholar
• DHAWAN J, RANDO TA, ELSON SL, BUJARD H, BLAU HM: Tetracycline-regulated gene expression following direct gene transfer into mouse skeletal muscle. SomaL Cell. MM. Genet. (1995) 4:233–240.
   Google Scholar
• RENDAHL KG, LEFF SE, OTTEN GR et al.: Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat. Biotechnol (1998) 16:757–761.
   PubMed Web of Science ®Google Scholar
• DALLE B, HENRI A, ROUYER-FESSARD P et al.: Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood (2001) 97:3776–3782.
   PubMed Web of Science ®Google Scholar
• BOHL D, SALVETTI A, MOULLIER P, HEARD JM: Control of erythropoietin delivery by doxycycline in mice afterintramuscular injection of adeno-associated vector. Blood (1998) 92:1512–1517.
   PubMed Web of Science ®Google Scholar
• RIZZUTO G, CAPELLETTI M, MAIONE D et al: Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc. Nati Acad. ScL USA (1999) 96:6417–6422.
   PubMed Web of Science ®Google Scholar
• ••Use of the tetracycline-inducible system forEpo expression in mice following plasmid delivery with electroporation.
   Google Scholar
• URLINGER S, BARON U, THELLMANN M, HASAN MT, BUJARD H, HILLEN W: Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc. Natl. Acad. Sci. USA (2000) 93:7963–7968.
   Google Scholar
• LAMARTINA S, ROSCILLI G, RINAUDO CD et al: Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators. Hum. Gene Ther. (2002) 13:199–210.
   PubMed Web of Science ®Google Scholar
• FORSTER K, LEDERER T,URLINGER S, WITTENBURG N, HILLEN W: Tetracycline-inducible expression systems with reduced basal activity in mammalian cells. Nuc. Acid Res. (1999) 7:708–710.
   Google Scholar
• RENDAHL KG, QUIROZ D,LADNER M et al.: Tightly regulated long-term erythropoietin expression in vivo using tet-inducible recombinant adeno-associated viral vectors. Hum. Gene Ther. (2002) 13:335–342.
   Google Scholar
• ••Incorporation of KRAB transcriptionalsilencing domain to reduce the basal activity of the tetracycline-inducible system. Produced long-term regulated Epo expression in mice.
   Google Scholar
• DELORT JP, CAPE CCHI MR: TAXI/UAS: a molecular switch to control expression of genes in vivo. Hum. Gene The]: (1996) 7:809–820.
   PubMed Web of Science ®Google Scholar
• BURCIN MM, SCHIEDNER G, KOCHANEK S et al.: Adenovirus-mediated regulable target gene expression M vivo. Proc. Natl. Acad. Sci. USA (1999) 96:355–360.
   PubMed Web of Science ®Google Scholar
• ABRUZZESE RV, GODIN D, BURCIN M et al.: Ligand-dependent regulation of plasmid-based transgene expression in vivo. Hum. Gene Ther (1999) 10:1499–1507.
   PubMed Web of Science ®Google Scholar
• •First use of the plasmid-based antiprogestin-inducible system in vivo.
   Google Scholar
• ABRUZZESE RV, GODIN D, MEHTA V et al.: Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Ma Their (2000) 2:276–287.
   PubMed Web of Science ®Google Scholar
• SPITZ IM, BARDIN CW: Mifepristone (RU 486)-a modulator of progestin and glucocorticoid action. N Engl.' Med. (1993) 329:404–412.
   PubMed Web of Science ®Google Scholar
• BELAN OFF JK, JURIK J,SCHATZBERG LD, DEBATTISTA C, SCHATZBERG AF: Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone.Neurosci. (2002) 19:201–206.
   Web of Science ®Google Scholar
• SARKAR NN: Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur. Obstet. Gynecol Reprod. Biol (2002) 101:113–120.
   PubMed Web of Science ®Google Scholar
• CROXATTO HB, KOVACS L, MASSAI R et al.: Effects of long-term low-dose mifepristone on reproductive function in women. Hum. Reprod. (1998) 4:793–798.
   Google Scholar
• CROXATTO HB, SALVATIERRA AM, CROXATTO HD, FUENTEALBA B: Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum. Reprod. (1993) 2:201–207.
   Google Scholar
• HEIKINHEIMO 0, HAUKKAMAA M, LAHTEENMAKI P: Distribution of RU 486 and its demethylated metabolites in humans. I Clin. Endocrinol Metab. (1989) 68:270–275.
   PubMed Web of Science ®Google Scholar
• TERADA Y, TANAKA H, OKADO T et al.: Ligand-regulatable erythropoietin production by plasmid injection and in vivo electroporation. Kidney Lir (2002) 62:1966–1976.
   PubMed Web of Science ®Google Scholar
• ••MFP regulated Epo expression in ratsfollowing plasmid delivery with electroporation.
   Google Scholar
• NORDSTROM JL: Antiprogestin-controllable transgene regulation in vivo. Curr. Opin. Biotechnoi (2002) 13:453–458.
   PubMed Web of Science ®Google Scholar
• ABRUZZESE RV, MACLAUGHLIN FC, SMITH LC, NORDSTROM JL: Regulated expression of plasmid based gene therapies. In: Gene Therapy Protocols, 2nd Edition (Molecular Medicine, Vol. 69), Morgan JR (Ed.), Humana Press, Totowa, NJ, (2001):109–122.
   Google Scholar
• MEHTA V, ABRUZZESE RV, BRUCE D et al.: Durable, ligand-dependent regulation of erythropoietin transgenes following intramuscular delivery of formulated plasmid to animals. Ma Their (2001) 3\(pt2 of 2):5397.
   Google Scholar
• •Long-term MFP regulated expression of EPO and haematocrit in mice and rats following plasmid delivery to muscle with electroporation. Short-term regulated expression of human EPOin dogs.
   Google Scholar
• DRAGHIA-AKLI R, MALONE PB, HILL LA, ELLIS KM, SCHWARTZ RJ, NORDSTROM JL: Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors. FASEB (2002) 16:426–428.
   PubMed Web of Science ®Google Scholar
• RIVERA VM, YE X, COURAGE N et al.: Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc. Nati Acad. Sci. USA (1999) 96:8657–8662.
   PubMed Web of Science ®Google Scholar
• •Use of the raparnycin-inducible system to produce long-term human growth hormone expression in mice.
   Google Scholar
• YE X, RIVERA VM, ZOLTICK P et al.: Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science (1999) 283:88–91.
   PubMed Web of Science ®Google Scholar
• ••Use of the raparnycin-inducible system forEpo expression in a non-human primate.
   Google Scholar
• RIVERA VM, GAO G-P, SCHNELL MA et al.: Long-term regulated delivery of Epo in non-human primates. MM. Ther. (2002) 4\(pt2 of 2):571.
   Google Scholar
• MADER S, WHITE JH: A steroid-inducible promoter for the controlled overexpression of cloned genes in eukaryotic cells. Proc. Natl. Acad. Sci. USA (1993) 90:5603–5607.
   PubMed Web of Science ®Google Scholar
• HALABY IA, LYDEN SP, DAVIES M et al.: Glucocorticoid-regulated VEGF expression in ischemic skeletal muscle. Ma The]: (2002) 5:300–306.
   PubMed Web of Science ®Google Scholar
• •System used to increase capillary density in ischaemic rat muscle.
   Google Scholar
• ADCOCK IM: Glucocorticoid-regulatedtranscription factors. Pulm. Pharmacol Ther: (2001) 14:211–219.
   PubMed Web of Science ®Google Scholar
• SEMENZA GL, ROTH PH, FANG HM, WANG GL:Transcriptional regulation of genes encoding glycolytic enzymes by hypwda-inducible factor 1. J. Biol. Chem. (1994) 269:23757–23763.
   PubMed Web of Science ®Google Scholar
• WANG GL, JIANG BH, RUE EA, SEMENZA GL: Hypwda-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular 02 tension. Proc. Nati Acad. Sci. USA (1995) 92:5510–5514.
   PubMed Web of Science ®Google Scholar
• IVAN M, KONDO K, YANG H et al: HIFalpha targeted for VHL-mediateddestruction by proline hydroxylation: implications for 02 sensing. Science (2001) 292:464–468.
   PubMed Web of Science ®Google Scholar
• JAKKOLA P, MOLE DR, TIAN TM et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by 02-regulated prolyl hydroxylation. Science (2001) 292:468–472.
   PubMed Web of Science ®Google Scholar
• BOAST K, BINLEY K, IQBALL S et al: Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum. Gene The]: (1999) 10:2197–2208.
   PubMed Web of Science ®Google Scholar
• RINSCH C, REGULIER E, DEGLON N, DALLE B, BEUZARD Y, AEBISCHER P: A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum. Gene Ther (1997) 8:1881–1889.
   PubMed Web of Science ®Google Scholar
• PRENTICE H, BISHOPRIC NH, HICKS MN et al.: Regulated expression of a foreign gene targeted to the ischaemic myocardium. Cardiovasc. Res. (1997) 35:567–574.
   PubMed Web of Science ®Google Scholar
• BINLEY K, ASKHAM Z, IQBALL S et al: Long-term reversal of chronic anemia using a hypoxia regulated erythropoietin gene therapy. Blood. (2002) 100:2406–2413.
   PubMed Web of Science ®Google Scholar
• ••In anaemic mice, long-term tightlyregulated Epo expression was observed using HREs that led to a normalisation of haematocrits and partial prevention of cardiac hypertrophy.
   Google Scholar
• TANGY, JACKSON M, QIAN K, PHILLIPS MI: Hypoxia inducible double plasmid system for myocardial ischemia gene therapy. Hypertension (2002)39\(part 2):695–698.
   Google Scholar
• ••Two-plasmid system using GAL4-p65amplification of the hypoxic response.
   Google Scholar
• PAYEN E, BETTAN M, HENRI A et al: Oxygen tension and a pharmacological switch in the regulation of transgene expression for gene therapy. Gene Med. (2001) 3:498–504.
   Google Scholar
• ••Use of a regulation system that is acombination of a drug- and metabolic-dependent system.
   Google Scholar
• THULE PM, LIU J, PHILLIPS LS: Glucose regulated production of human insulin in rat hepatocytes. Gene Their (2000) 7:205–214.
   PubMed Web of Science ®Google Scholar
• •Use of carbohydrate-responsive elements to produce a 4- to 5-fold increase in glucose stimulated insulin production in vitro in rat hepatocytes.
   Google Scholar
• THULE PM, LIU JM: Regulated hepaticinsulin gene therapy of STZ-diabetic rats. Gene Thec (2000) 7:1744–1752.
   PubMed Web of Science ®Google Scholar
• SHAW JA, DELDAY MI, HART AW, DOCHERTY HM, MALTIN CA, DOCHERTY K: Secretion of bioactive human insulin following plasmid-mediated gene transfer to non-neuroendocrine cell lines, primary cultures and rat skeletal muscle M vivo. J. EndocrinoL (2002) 172:653–672.
   PubMed Web of Science ®Google Scholar
• YIN D, TANG JG: Gene therapy for streptozotocin-induced diabetic mice by electroporation transfer of naked humanainsulin precursor DNA into skeletal muscle in viva FEBS Lett. (2001) 495:16–20.
   Google Scholar
• MCHUTCHISON JG: Hepatitis C advances in antiviral therapy: what is accepted treatment now?' Gastroenterol. Hepatol. (2002) 17:431–441.
   Web of Science ®Google Scholar
• POCKROS PJ: Developments in the treatment of chronic hepatitis C. Expert Opin. Investig. Drugs (2002) 11:515–528.
   PubMed Web of Science ®Google Scholar
• LATTA-MAHIEU M, ROLLAND M, CAILLET C et al.: Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgeneexpression. Hum. Gene Ther. (2002) 13:1611–1620.
   PubMed Web of Science ®Google Scholar